Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Palvella Therapeutics (PVLA) Non-cash Items (2016 - 2026)

Palvella Therapeutics has reported Non-cash Items over the past 3 years, most recently at $108000.0 for Q4 2021.

Quarterly Non-cash Items changed N/A to $108000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $108000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $9.1 million for FY2022, 8322.22% up from the prior year.
Non-cash Items was $108000.0 for Q4 2021 at Palvella Therapeutics, down from $228774.0 in the prior quarter.
Over five years, Non-cash Items peaked at $108000.0 in Q4 2021 and troughed at $108000.0 in Q4 2021.